Olanzapine Mylan 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
IB/0057 
B.II.d.1.z - Change in the specification parameters 
19/05/2023 
SmPC and PL 
and/or limits of the finished product - Other variation 
N/0056 
Minor change in labelling or package leaflet not 
12/01/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are 
issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD 
is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
IAIN/0055 
B.II.b.2.c.1 - Change to importer, batch release 
22/11/2021 
28/11/2022 
Annex II and PL 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - Not 
including batch control/testing 
T/0054 
Transfer of Marketing Authorisation 
15/09/2021 
12/11/2021 
SmPC, 
Labelling and 
PL 
IB/0053 
B.II.d.1.c - Change in the specification parameters 
06/07/2021 
n/a 
and/or limits of the finished product - Addition of a 
new specification parameter to the specification with 
its corresponding test method 
IA/0052 
A.7 - Administrative change - Deletion of 
05/03/2021 
12/11/2021 
Annex II and PL 
manufacturing sites 
IB/0051 
B.III.1.a.2 - Submission of a new/updated or deletion 
17/09/2020 
n/a 
of Ph. Eur. Certificate of Suitability to the relevant Ph. 
Eur. Monograph - Updated certificate from an already 
approved manufacturer 
IA/0050/G 
This was an application for a group of variations. 
31/07/2020 
n/a 
B.I.b.2.a - Change in test procedure for AS or starting 
material/reagent/intermediate - Minor changes to an 
approved test procedure 
B.III.1.a.2 - Submission of a new/updated or deletion 
of Ph. Eur. Certificate of Suitability to the relevant Ph. 
Eur. Monograph - Updated certificate from an already 
approved manufacturer 
Page 2/16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.III.1.a.2 - Submission of a new/updated or deletion 
of Ph. Eur. Certificate of Suitability to the relevant Ph. 
Eur. Monograph - Updated certificate from an already 
approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or deletion 
of Ph. Eur. Certificate of Suitability to the relevant Ph. 
Eur. Monograph - Updated certificate from an already 
approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or deletion 
of Ph. Eur. Certificate of Suitability to the relevant Ph. 
Eur. Monograph - Updated certificate from an already 
approved manufacturer 
IB/0049 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
02/06/2020 
28/08/2020 
SmPC, Annex 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Other variation 
II, Labelling 
and PL 
IB/0048 
C.I.2.a - Change in the SPC, Labelling or PL of a 
31/07/2019 
28/08/2020 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by the 
MAH 
N/0047 
Minor change in labelling or package leaflet not 
07/03/2019 
28/08/2020 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0046 
B.II.d.2.a - Change in test procedure for the finished 
14/11/2018 
n/a 
product - Minor changes to an approved test 
procedure 
Page 3/16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T/0045 
Transfer of Marketing Authorisation 
19/09/2018 
12/11/2018 
SmPC, 
Labelling and 
PL 
IA/0044 
B.II.e.1.a.1 - Change in immediate packaging of the 
13/07/2018 
12/11/2018 
SmPC, 
finished product - Qualitative and quantitative 
composition - Solid pharmaceutical forms 
Labelling and 
PL 
IB/0043 
C.I.2.a - Change in the SPC, Labelling or PL of a 
12/12/2017 
12/11/2018 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by the 
MAH 
IAIN/0042 
C.I.z - Changes (Safety/Efficacy) of Human and 
07/02/2017 
25/07/2017 
SmPC, 
Veterinary Medicinal Products - Other variation 
Labelling and 
PL 
IA/0041 
A.5.b - Administrative change - Change in the name 
12/12/2016 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IB/0040 
C.I.z - Changes (Safety/Efficacy) of Human and 
21/07/2016 
25/07/2017 
SmPC, 
Veterinary Medicinal Products - Other variation 
Labelling and 
PL 
IG/0647 
C.I.8.a - Introduction of or changes to a summary of 
11/01/2016 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the PSMF 
location 
Page 4/16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0038 
C.I.2.a - Change in the SPC, Labelling or PL of a 
02/07/2015 
06/07/2016 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by the 
MAH 
Labelling and 
PL 
IAIN/0037 
B.III.1.a.1 - Submission of a new/updated or deletion 
16/03/2015 
n/a 
of Ph. Eur. Certificate of Suitability to the relevant Ph. 
Eur. Monograph - New certificate from an already 
approved manufacturer 
IA/0036 
A.5.b - Administrative change - Change in the name 
13/10/2014 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IB/0034/G 
This was an application for a group of variations. 
31/10/2013 
19/08/2014 
SmPC, 
Labelling and 
PL 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. tablets, 
ampoules, etc.) in a pack - Change outside the range 
of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. tablets, 
ampoules, etc.) in a pack - Change within the range of 
the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. tablets, 
ampoules, etc.) in a pack - Change outside the range 
of the currently approved pack sizes 
Page 5/16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0035 
A.7 - Administrative change - Deletion of 
24/10/2013 
n/a 
manufacturing sites 
IB/0033 
C.I.2.a - Change in the SPC, Labelling or PL of a 
19/08/2013 
19/08/2014 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
R/0032 
Renewal of the marketing authorisation. 
21/03/2013 
22/05/2013 
Annex II 
Based on the CHMP review of the available information and 
IA/0031 
A.5.b - Administrative change - Change in the name 
27/09/2012 
n/a 
and/or address of a manufacturer of the finished 
product, including quality control sites (excluding 
manufacturer for batch release) 
IB/0030 
C.I.2.a - Change in the SPC, Labelling or PL of a 
26/09/2012 
25/10/2012 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
II, Labelling 
and PL 
on the basis of a re-evaluation of the benefit risk balance, the 
CHMP was of the opinion that the quality, safety and efficacy 
of this medicinal product continues to be adequately and 
sufficiently demonstrated and therefore considered that the 
benefit risk profile of Olanzapine Mylan continues to be 
favourable. 
The CHMP was of the opinion that the renewal could be 
granted with unlimited validity. 
Page 6/16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0029/G 
This was an application for a group of variations. 
18/01/2012 
03/08/2012 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
IB/0028 
To add a new unit dose pack size of 100x1 tablets for 
12/10/2011 
12/10/2011 
SmPC, 
the 7.5mg film-coated tablets (EU/1/08/475/057). 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. tablets, 
ampoules, etc.) in a pack - Change outside the range 
of the currently approved pack sizes 
Labelling and 
PL 
IA/0027/G 
This was an application for a group of variations. 
12/10/2011 
12/10/2011 
SmPC, Annex 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
II, Labelling 
and PL 
Page 7/16 
 
 
 
 
 
 
 
 
 
 
 
 
 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging site 
B.II.b.2.a - Change to batch release arrangements 
and quality control testing of the FP - Replacement or 
addition of a site where batch control/testing takes 
place 
B.II.b.2.b.1 - Change to batch release arrangements 
and quality control testing of the FP - Not including 
batch control/testing 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. tablets, 
ampoules, etc.) in a pack - Change within the range of 
the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. tablets, 
ampoules, etc.) in a pack - Change within the range of 
the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. tablets, 
ampoules, etc.) in a pack - Change within the range of 
the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. tablets, 
ampoules, etc.) in a pack - Change within the range of 
the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. tablets, 
ampoules, etc.) in a pack - Change within the range of 
the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. tablets, 
Page 8/16 
 
 
 
 
 
ampoules, etc.) in a pack - Change within the range of 
the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. tablets, 
ampoules, etc.) in a pack - Change within the range of 
the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. tablets, 
ampoules, etc.) in a pack - Change within the range of 
the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. tablets, 
ampoules, etc.) in a pack - Change within the range of 
the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. tablets, 
ampoules, etc.) in a pack - Change within the range of 
the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. tablets, 
ampoules, etc.) in a pack - Change within the range of 
the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. tablets, 
ampoules, etc.) in a pack - Change within the range of 
the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. tablets, 
ampoules, etc.) in a pack - Change within the range of 
the currently approved pack sizes 
Page 9/16 
 
 
 
 
 
 
IB/0023 
B.I.d.1.z - Stability of AS - Change in the re-test 
04/08/2011 
n/a 
period/storage period or storage conditions - Other 
variation 
IB/0020 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf life 
06/07/2011 
n/a 
SmPC, 
of the finished product - As packaged for sale 
(supported by real time data) 
Labelling and 
PL 
IB/0022/G 
This was an application for a group of variations. 
05/07/2011 
n/a 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
B.I.b.1.h - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition or 
replacement (excl. Biol. or immunol. substance) of a 
specification parameter as a result of a safety or 
quality issue 
B.I.c.2.b - Change in the specification parameters 
and/or limits of the immediate packaging of the AS - 
Addition of a new specification parameter to the 
specification with its corresponding test method 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or supplier of the 
AS, starting material, reagent or intermediate used in 
the manufacture of the AS 
IB/0021/G 
This was an application for a group of variations. 
01/07/2011 
01/07/2011 
SmPC, Annex 
B.II.e.5.a.1 - Change in pack size of the finished 
II, Labelling 
and PL 
Page 10/16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
product - Change in the number of units (e.g. tablets, 
ampoules, etc.) in a pack - Change within the range of 
the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. tablets, 
ampoules, etc.) in a pack - Change outside the range 
of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. tablets, 
ampoules, etc.) in a pack - Change within the range of 
the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. tablets, 
ampoules, etc.) in a pack - Change within the range of 
the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. tablets, 
ampoules, etc.) in a pack - Change within the range of 
the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. tablets, 
ampoules, etc.) in a pack - Change within the range of 
the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. tablets, 
ampoules, etc.) in a pack - Change within the range of 
the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. tablets, 
ampoules, etc.) in a pack - Change within the range of 
the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
Page 11/16 
 
 
 
 
 
product - Change in the number of units (e.g. tablets, 
ampoules, etc.) in a pack - Change outside the range 
of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. tablets, 
ampoules, etc.) in a pack - Change outside the range 
of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. tablets, 
ampoules, etc.) in a pack - Change outside the range 
of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. tablets, 
ampoules, etc.) in a pack - Change outside the range 
of the currently approved pack sizes 
IA/0024/G 
This was an application for a group of variations. 
16/06/2011 
n/a 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
Page 12/16 
 
 
 
 
 
 
 
 
 
corresponding test method 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
IA/0019/G 
This was an application for a group of variations. 
05/01/2011 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging site 
B.II.b.2.a - Change to batch release arrangements 
and quality control testing of the FP - Replacement or 
addition of a site where batch control/testing takes 
place 
Page 13/16 
 
 
 
 
 
 
 
 
 
 
IB/0018 
C.I.2.a - Change in the SPC, Labelling or PL of a 
15/11/2010 
n/a 
SmPC 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
IB/0017 
B.II.b.5.z - Change to in-process tests or limits applied 
20/07/2010 
n/a 
during the manufacture of the finished product - Other 
variation 
IB/0016 
C.I.2.a - Change in the SPC, Labelling or PL of a 
22/03/2010 
n/a 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
IB/0004 
IB_33_Minor change in the manufacture of the 
22/01/2010 
n/a 
finished product 
IB/0003 
IA_09_Deletion of manufacturing site 
22/01/2010 
n/a 
IB_07_c_Replacement/add. of manufacturing site: All 
other manufacturing operations ex. batch release 
IA/0015 
IA_09_Deletion of manufacturing site 
18/12/2009 
n/a 
Annex II and PL 
IA/0014 
IA_09_Deletion of manufacturing site 
18/12/2009 
n/a 
Annex II and PL 
IA/0013 
IA_09_Deletion of manufacturing site 
18/12/2009 
n/a 
Annex II and PL 
IA/0012 
IA_09_Deletion of manufacturing site 
18/12/2009 
n/a 
Annex II and PL 
Page 14/16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0011 
IA_09_Deletion of manufacturing site 
18/12/2009 
n/a 
IA/0010 
IA_09_Deletion of manufacturing site 
18/12/2009 
n/a 
IA/0009 
IA_09_Deletion of manufacturing site 
18/12/2009 
n/a 
IA/0008 
IA_09_Deletion of manufacturing site 
18/12/2009 
n/a 
IA/0007 
IA_07_a_Replacement/add. of manufacturing site: 
18/12/2009 
n/a 
Secondary packaging site 
IA/0006 
IA_05_Change in the name and/or address of a 
18/12/2009 
n/a 
Annex II and PL 
manufacturer of the finished product 
IA/0005 
IA_07_a_Replacement/add. of manufacturing site: 
18/12/2009 
n/a 
Secondary packaging site 
II/0002 
Update to section 4.8 of the Summary of Product 
24/09/2009 
23/10/2009 
SmPC and PL 
The SPC was updated to align it with that of the reference 
Characteristics (SPC) in line with the Product 
Information of the reference medicinal product. An 
editorial change was made in section 4.4 of the SPC. 
In addition, the Marketing Authorisation Holder took 
the opportunity to update the contact details for the 
local representative in Slovakia in the Package Leaflet 
and to introduce minor linguistic changes in the 
Bulgarian, Danish, Dutch, French, German, Greek, 
Hungarian, Italian, Latvian, Lithuanian, Polish, 
Portuguese, Romanian and Swedish Annexes. 
Update of Summary of Product Characteristics and 
Package Leaflet 
medicinal product. This followed a change to the SPC of the 
reference medicinal product via the following procedure: 
Zyprexa (EMEA/H/C/000115/II/0099). 
Page 15/16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II/0001 
Update to sections 4.4 and 4.9 of the Summary of 
25/06/2009 
17/07/2009 
SmPC 
Following changes to the SPC of the reference medicinal 
Product Characteristics (SPC) in line with the Product 
Information of the reference product Zyprexa. 
Update of Summary of Product Characteristics 
product Zyprexa, sections 4.4 and 4.9 of the Olanzapine 
Mylan SPC were updated. Recommendations on monitoring 
of patients for signs and symptoms of hyperglycaemia, 
worsening of glucose control and weight gain were added to 
section 4.4 and new information on acute overdose was 
added to section 4.9. 
The summary of the above mentioned changes may be found 
in the EPARs (module 8B) of Zyprexa (II/96) and Zyprexa 
Velotab (II/68). 
Page 16/16 
 
 
 
 
 
 
 
 
 
